Literature DB >> 9602421

The statistics of synergism.

B K Slinker1.   

Abstract

Biological scientists often want to determine whether two agents or events, for example, extracellular stimuli and/or intracellular signaling pathways, act synergistically when eliciting a biological response. When setting out to study whether two experimental treatments act synergistically, most biologists design the correct experiment--they administer four treatment combinations consisting of (1) the first treatment alone, (2) the second treatment alone, (3) both treatments together, and (4) neither treatment (i.e. the control). Many biologists are less clear about the correct statistical approach to determining whether the data collected in such an experimental design support a conclusion regarding synergism, or lack thereof. The non-additivity of two experimental treatments that is central to the definition of synergism leads to an algebraic formulation corresponding to the statistical null hypothesis appropriate for testing whether or not there is synergism. The resulting complex contrast among the four treatment group means is identical to the interaction effect tested in a two-way analysis of variance (ANOVA). This should not be surprising, because synergism, by definition, occurs when two treatments interact, rather than act independently, to influence a biological response. Hence, in the most readily implemented approach, the correct statistical analysis of a question of synergism is based on testing the interaction effect in a two-way ANOVA. This review presents the rationale for this correct approach to analysing data when the question is of synergism, and applies this approach to a recent published example. In addition, a common incorrect approach to analysing data with regards to synergism is presented. Finally, several associated statistical issues with regard to correctly implementing a two-way ANOVA are discussed.

Mesh:

Year:  1998        PMID: 9602421     DOI: 10.1006/jmcc.1998.0655

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  113 in total

1.  Mechanisms underlying the synergistic enhancement of self-assembled neocartilage treated with chondroitinase-ABC and TGF-β1.

Authors:  Donald J Responte; Boaz Arzi; Roman M Natoli; Jerry C Hu; Kyriacos A Athanasiou
Journal:  Biomaterials       Date:  2012-01-26       Impact factor: 12.479

2.  Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.

Authors:  Katie L Propst; Ryan M Troyer; Lisa M Kellihan; Herbert P Schweizer; Steven W Dow
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

3.  Enhanced antiscrapie effect using combination drug treatment.

Authors:  David A Kocisko; Byron Caughey; John D Morrey; Richard E Race
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

4.  Activin and glucocorticoids synergistically activate follicle-stimulating hormone beta-subunit gene expression in the immortalized LbetaT2 gonadotrope cell line.

Authors:  Shauna M McGillivray; Varykina G Thackray; Djurdjica Coss; Pamela L Mellon
Journal:  Endocrinology       Date:  2006-11-02       Impact factor: 4.736

5.  Hyperglycemia accentuates persistent "functional uncoupling" of cerebral microvascular nitric oxide and superoxide following focal ischemia/reperfusion in rats.

Authors:  Roderic H Fabian; Thomas A Kent
Journal:  Transl Stroke Res       Date:  2012-09-05       Impact factor: 6.829

6.  Sirtuin 1-mediated effects of exercise and resveratrol on mitochondrial biogenesis.

Authors:  Keir J Menzies; Kaustabh Singh; Ayesha Saleem; David A Hood
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

7.  Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.

Authors:  Margaret Nieborowska-Skorska; Silvia Maifrede; Min Ye; Monika Toma; Elizabeth Hewlett; John Gordon; Bac Viet Le; Tomasz Sliwinski; Huaqing Zhao; Katarzyna Piwocka; Peter Valent; Alexei V Tulin; Wayne Childers; Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2018-10-02

8.  Targeting BTK through microRNA in chronic lymphocytic leukemia.

Authors:  Arianna Bottoni; Lara Rizzotto; Tzung-Huei Lai; Chaomei Liu; Lisa L Smith; Rose Mantel; Sean Reiff; Dalia El-Gamal; Karilyn Larkin; Amy J Johnson; Rosa Lapalombella; Amy Lehman; William Plunkett; John C Byrd; James S Blachly; Jennifer A Woyach; Deepa Sampath
Journal:  Blood       Date:  2016-10-17       Impact factor: 22.113

9.  PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

Authors:  Xiu Feng Hu; Jie Li; Scott Vandervalk; Zeping Wang; Nancy S Magnuson; Pei Xiang Xing
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

10.  Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Authors:  Jahan P Marcu; Rigel T Christian; Darryl Lau; Anne J Zielinski; Maxx P Horowitz; Jasmine Lee; Arash Pakdel; Juanita Allison; Chandani Limbad; Dan H Moore; Garret L Yount; Pierre-Yves Desprez; Sean D McAllister
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.